非小细胞肺癌靶向治疗的耐药特点及应对策略

Resistance characteristics and countermeasures of targeted therapy in non-small cell lung cancer

分子靶向治疗在驱动基因阳性的晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者中已经获得显著的疗效,但靶向治疗后期发生的耐药问题也成为了非小细胞肺癌进一步治疗的难题。现有分子靶向治疗中已知多种肿瘤驱动基因靶点,常见的有EGFR、ALK、ROS1、HER-2、BRAF、MET等。本文将对上述基因突变靶点抑制剂的耐药特点及耐药后的进一步治疗进行综述。

Molecular targeted therapy has shown significant efficacy in advanced non-small cell lung cancer patients with positive driver genes.However, the drug resistance problem that occurs in the later stage of targeted therapy has become a block for further treatment in non-small cell lung cancer.A variety of tumor-driving gene targets are known in existing molecular targeted therapy, the common ones are EGFR,ALK,ROS1,HER-2,BRAF,MET,and so on.This review will introduce the resistance characteristics of those gene mutation target inhibitors and summarize the further treatment after drug resistance.